GlucoTrack, Inc.

Equities

GCTK

US45824Q6061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-05 EDT			5-day change	1st Jan Change
1.74 ^USD	+0.61%		-13.43%	+33.08%

07-01	GlucoTrack, Inc. announced that it has received $0.1 million in funding	CI
06-20	Glucotrack Announces the Appointment of Andy Balo to Board of Directors	CI

Integrity Applications, Inc. Appoints Eran Cohen as Chief Operating Officer

January 11, 2016 at 02:34 pm

Effective January 1, 2016, Eran Cohen was appointed to serve as Chief Operating Officer of Integrity Applications, Inc. and A.D. Integrity Applications Ltd. Mr. Cohen, 57, served in positions of increasing responsibility at Lumenis Ltd. from 2012 to 2015, including most recently as Vice President of Global Services. From 2008 until 2012, Mr. Cohen served as Vice President of Operations at Cadent Ltd.

Latest news about GlucoTrack, Inc.

GlucoTrack, Inc. announced that it has received $0.1 million in funding	06-30	CI
Glucotrack Announces the Appointment of Andy Balo to Board of Directors	06-20	CI
Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor	06-13	CI
Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor	06-05	CI
Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	05-16	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
GlucoTrack, Inc. announced that it has received $0.5 million in funding	04-21	CI
Glucotrack Expanding Glucose Monitoring Technology to Epidural Space	04-16	MT
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring	04-16	CI
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor	04-02	CI
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors	02-13	CI
GlucoTrack Says Implantable Glucose Monitor Safe With High Level of Accuracy; Shares Rise	01-02	MT
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor	01-02	CI
GlucoTrack, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
GlucoTrack Finance Chief Jolie Kahn Resigns, James Cardwell Named New CFO	23-10-12	MT
GlucoTrack, Inc. Announces Executive Changes	23-10-12	CI
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee	23-08-31	CI
GlucoTrack, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor	23-07-25	CI
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2023.	23-06-12	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GlucoTrack Completes $10 Million Share Sale	23-04-17	MT
Top Midday Decliners	23-04-13	MT
GlucoTrack Prices $10 Million Securities Offering; Shares Slump	23-04-13	MT

Chart GlucoTrack, Inc.

Duration

Period

More charts

Company Profile

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLUCOTRACK, INC.	+33.08%	9.53M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research